1. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Issue 3 (March 2020) Authors: Sequist, Lecia V; Han, Ji-Youn; Ahn, Myung-Ju; Cho, Byoung Chul; Yu, Helena; Kim, Sang-We; Yang, James Chih-Hsin; Lee, Jong Seok; Su, Wu-Chou; Kowalski, Dariusz; Orlov, Sergey; Cantarini, Mireille; Verheijen, Remy B; Mellemgaard, Anders; Ottesen, Lone; Frewer, Paul; Ou, Xiaoling; Oxnard, Geoffrey Journal: Lancet oncology Issue: Volume 21:Issue 3(2020) Page Start: 373 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Decision‐making in early clinical drug development. (17th March 2016) Authors: Frewer, Paul; Mitchell, Pat; Watkins, Claire; Matcham, James Journal: Pharmaceutical statistics Issue: Volume 15:Number 3(2016) Page Start: 255 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Clinical evaluation of the potential drug–drug interactions of savolitinib: Interaction with rifampicin, itraconazole, famotidine or midazolam. Issue 2 (21st August 2021) Authors: Ren, Song; Vishwanathan, Karthick; Cantarini, Mireille; Frewer, Paul; Hara, Indira; Scarfe, Graeme; Burke, Wendy; Schalkwijk, Stein; Li, Yan; Han, David; Goldwater, Ronald Journal: British journal of clinical pharmacology Issue: Volume 88:Issue 2(2022) Page Start: 655 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗